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In cell culture. rabbit vascular smooth muscle cells were infected in a simi-
lar manner. Ii-Galactosidase staining was present at all 3 viral concentrations
but when a viral concentration of 1 x 1010 pfulml was used there were areas
of cellular necrosis not seen at the lower viral concentrations,
Conclusion: Replication-deficient adenovirus vectors can rapidly and effi-
ciently infect rabbit carotid vessels. However at doses often employed for
gene transfer experiments in-vivo, there is a dose dependent alteration of
vessel vasomotor function which may be mediated by a cytotoxic affect of
the viral vector, This effect needs to be taken into account in studies involving
adenoviral gene transfer.
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Coronary atherosclerosis and restenosis are disease processes involving cell
proliferation and activation of growth factors. Endothelin-l (ET-l). a vaso-
constrictor and mitogenic peptide, is produced from its precursor Big-ET.
Coronary plasma ET concentrations are elevated in coronary atherosclero-
sis and following coronary interventions. The current study was designed
to test the hypothesis that ET is produced and present in human coronary
atherosclerotic and restenotic lesions and localized to both endothelial and
nonendothelial cells. Twenty coronary lesions were obtained utilizing direc-
tional atherectomy. Immunohistochemistry for endothelins was performed
with rabbit polyclonal ET-l and Big-ET antiserum without cross reactivity be-
Background: Recent studies suggest that the release of tissue factor (TF) and
its interaction with factor VII at the site of vascular injury may be the activator
of the coagulation cascade, which along with platelet aggregation leads to
occlusive intravascular thrombus formation. We tested this hypothesis in a
rabbit carotid artery model of thrombosis.
Methods: Carotid artery was instrumented with Doppler flow probe and
a needle electrode. Partially occlusive thrombus was formed by applying
150 J.l.A of current which damages the endothelium of the carotid artery
and promotes thrombus formation. After development of 50% occlusion of
the artery by thrombus. the current was stopped and a murine monoclonal
antibody against rabbit TF (AP-l) (0.1 mglkg intraarterially) or vehicle (con-
trol) was administered. The changes in carotid blood flow were continuously
monitored by the Doppler flow probe. Bleeding was assessed by weigh-
ing the amount of blood absorbed in a preweighed sponge, placed in a cut
wound that was 5 cm long and 0.5 cm deep.
Results: The control rabbits (n = 12) occluded their arteries in 46.2 ± 13.6
min after stopping the current by a fibrin-platelet thrombus. In contrast, AP-l
prevented carotid artery occlusion for >200 min (n = 6) (p > 0.0001). Lower
doses of AP-l were ineffective. The deep incisional bleeding times were not
different between the control animals and the treated group, Similarly the
platelet counts or ex vivo platelet aggregation response to collagen, ADP
or arachidoic acid were not different between the control and the treated
animals.
Conclusion: Data suggest that TF released at the site of vascular injury
plays a role in intravascular coagulation and its activity can be selectively
inhibited, without inducing an alteration in hemostatic parameters or platelet
functions.
normal (non-cholesterol and non-treated) rabbits were evaluated as well. The
vasoreactive response to acetylcholine, serotonin and nitroprusside were
calculated from flow velocity measured by Doppler wire, vessel diameter
obtained from angiograms. and intra-arterial blood pressure recorded at
the proximal external iliac artery. The resistance response to endothelium-
dependent and -independent agonists recovered in VEGF group, as illus-
trated below. Furthermore, average intimal thickness of external iliac artery
and lower abdominal aorta in VEGF group was significantly less than control
group (VEGF = 0.010 ± 0.008 vs control = 0,106 ± 0.036, P < 0,05). Con-
clusion: Intermittent systemic administration of VEGF improves endothelial
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Gene transfer technologies offer great potential both to investigate and alter
the course of vessel wall pathophysiology. Replication-deficient adenovirus
vectors appear particularly useful for the transfection of blood vessels, be-
cause. of their ability to accommodate large cDNA inserts and to rapidly and
efficiently infect mammalian cells. However, the potential effects of transfec-
tion with a replication-deficient adenovirus on vasomotor function have not
been previously described. We performed gene transfer experiments with
a replication-deficient adenovirus which contained a cytomegalovirus pro-
moter and a nuclear-localizing variant of the bacterial Ii-galactosidase gene.
Excised carotid artery segments from 6 rabbits were divided into multiple
segments and infected in pairs. for 30 minutes with four different viral titers
(0,2,5 x 109.5 x 109, 1 x 1010 pfu/ml) at 3rC in serum free media. These
segments were tested for Ii-galactosidase staining and vasomotor function
2 days later. Isometric tension studies were performed to examine the re-
sponse of the vessel segments to the contractile agonist. norepinephrine
(NE). The results are shown below as mean ± standard error. -log lO lEC501
with * p :::: 0.04 between the lowest and the highest group.
embryonic kidney epithelial cells which are competent to replicate these
adenoviral vectors (293 cells). The vector incorporating the SMA promoter
demonstrated substantial selectivity for vascular smooth muscle gene ex-
pression. with typical transductions carried out in parallel under identical
conditions manifesting 90-95% lacZ-expressing BASMC. 0.3% lacZ-positive
A549 cells. and 4% positive 293 cells. Conversely, parallel transductions with
the vector employing the RSV promoter typically resulted in 95-99% lacZ-
expressing 293 cells at vector concentrations yielding only 5-10% positive
BASMC. These data support cell lineage-specificity of AvLacZ5 at the level of
promoter function rather than due to intrinsic cellular differences in capacity
for adenovirally-mediated transduction. However, it is notable that a limited
subpopulation of 293 cells clearly are able to direct sufficient transcription
from the SMA promoter sequences chosen to yield detectable lacZ expres-
sion; the molecular basis for this heterogeneity of expression remains to be
determined. Adenoviral vectors utilizing these promoter sequences may ren-
der vascular-restricted gene transfer feasible when used in conjunction with
mechanical devices providing a component of spatial localization.
Endothelial dysfunction in hypercholesterolemia causes abnormal arterial va-
soreactivity and precedes the onset of atherosclerosis, Vascular endothelial
growth factor (VEGF) is an endothelial cell (Ee) specific mitogen that has
been shown to stimulate EC proliferation in vitro and in vivo. We investi-
gated the hypothesis that VEGF could also modulate EC dysfunction and
thereby improve endothelium-dependent vasoreactivity. impaired due to hy-
percholesterolemia. Hypercholesterolemic rabbits fed a 1% cholesterol diet
for 6 weeks were treated with intravenous administration of 300 J.l.g VEGF
(VEGF group; n ~ 8) or 0.9% saline solution (control group; n = 91 twice
a week for 3 weeks, during which time both groups continued to receive
cholesterol diet. All rabbits were evaluated by in vivo vasomotion study; 8
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